{"id":4126,"date":"2026-11-03T09:00:00","date_gmt":"2026-11-03T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4126"},"modified":"2026-11-07T16:07:50","modified_gmt":"2026-11-07T20:07:50","slug":"relcobatinib-paper-maps-selective-bcr-abl1-binding","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4126","title":{"rendered":"Relcobatinib Paper Maps Selective BCR ABL1 Binding"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"768\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Enliven_Therapeutics_Technology_and_Modalities-768x768.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4144\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Enliven_Therapeutics_Technology_and_Modalities-768x768.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Enliven_Therapeutics_Technology_and_Modalities-300x300.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Enliven_Therapeutics_Technology_and_Modalities-1024x1024.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Enliven_Therapeutics_Technology_and_Modalities-150x150.png 150w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261106_Enliven_Therapeutics_Technology_and_Modalities.png 1254w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Enliven Therapeutics<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Peer-reviewed publication (Leukemia)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Small molecule<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Relcobatinib (ELVN-001)<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>BCR::ABL1 (active site)<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Chronic myeloid leukemia<\/p>\n<h4>Summary<\/h4>\n<p>Previously missed November 3 online Leukemia article describes the structure and preclinical selectivity of relcobatinib (ELVN-001), an active-site BCR::ABL1 inhibitor already in CML clinical trials. The publication adds mechanistic evidence; it is not a new clinical readout.<\/p>\n<p>Crystallography supports a folded-in P-loop binding mode. Investigators report activity against native BCR::ABL1 and resistant variants including T315I, relative kinome selectivity, mouse xenograft activity, and greater regression with asciminib combination. The paper is distinct from Enliven\u2019s October 6 announcement of FDA alignment on the planned Phase 3 design.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> selective active-site inhibition plus allosteric asciminib could broaden resistance coverage while avoiding off-target toxicities of older TKIs. Structural and xenograft data support testing. Counterargument: tolerability and molecular response superiority need randomized patient evidence, and combined inhibition may add toxicity or resistance pathways.<\/p>\n<p><strong>Interpretation B:<\/strong> the paper may be confirmatory support for an already advanced asset rather than a new platform inflection. Phase 3 comparative MMR, adverse-event discontinuation, mutation-specific outcomes and long-term progression would decide.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Chronic myeloid leukemia is driven by BCR::ABL1 fusion kinase. Relcobatinib is an investigational ATP-competitive small molecule; asciminib binds the ABL myristoyl pocket allosterically.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Company-associated authors and preclinical systems are not independent clinical validation.<\/li>\n<li>Kinase selectivity, CML stem-cell persistence, cardiovascular safety, chronic dosing and drug-drug interactions remain translational constraints.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>Mechanistic publication strengthens the rationale for a head-to-head CML trial but cannot establish best-in-class status.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 3 of 5. Signal Direction: positive for mechanistic evidence; uncertain for clinical differentiation. Confidence in Facts: high for peer-reviewed preclinical work. Confidence in Interpretation: moderate-low.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Previously missed November 3 online Leukemia article describes the structure and preclinical selectivity of relcobatinib (ELVN-001), an active-site BCR::ABL1 inhibitor already in CML clinical trials. The publication adds mechanistic evidence; it is not a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4144,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[946,942,943],"class_list":["post-4126","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-chronic-myeloid-leukemia","tag-enliven-therapeutics","tag-relcobatinib"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4126"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4126\/revisions"}],"predecessor-version":[{"id":4148,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4126\/revisions\/4148"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4144"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}